Recruitment status
- Recruiting60
- Completed52
- Active, not recruiting25
- Not yet recruiting22
- Withdrawn7
- Terminated5
- Unknown status3
- Enrolling by invitation2
Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
United States trial landscape
Psilocybin Clinical Trials in the United States
Compare psilocybin studies with at least one registry-listed site in the United States, including recruiting status, conditions, phases, sponsors, and locations.
Registry status is not a guarantee of local availability, eligibility, safety, or efficacy. Confirm every participation decision in the authoritative ClinicalTrials.gov record.
177matching trials
60currently recruiting
330registry-listed sites
Registry facts checkedAug 10, 2026 01:26 UTC
Live registry synthesis
Status, geography, and study phase
Country inclusion is based on structured study-site data, not sponsor location. A multinational trial appears here when at least one indexed site is in the United States.
Leading countries
- United States177
- Ireland5
- United Kingdom5
- Czechia3
- Netherlands3
- Canada2
- Denmark2
- Germany2
Trial phases
- Phase 286
- Phase 174
- Early Phase 116
- Phase 38
- Not applicable3
Server-rendered source index
177 matching registry records
Every factual summary is crawlable without JavaScript. Use the direct registry link for current eligibility, contacts, and site availability.
Not yet recruitingNCT07721467
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's Disease
National Institute on Aging (NIA)
- Conditions
- Alzheimer's Disease
- Phase
- Phase 2
- Enrollment
- 200 estimated
- Locations
- National Institute of Aging, Clinical Research Unit, Baltimore, Maryland, United States
- Registry updated
- 2026-08-07
RecruitingNCT06349083
Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use Disorder
NYU Langone Health
- Conditions
- Alcohol Use Disorder
- Phase
- Phase 2
- Enrollment
- 200 estimated
- Locations
- NYU Langone Health, New York, New York, United States
- Registry updated
- 2026-08-07
RecruitingNCT06455293
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease
Joshua Woolley, MD, PhD
- Conditions
- Parkinson Disease · Depression
- Phase
- Phase 2
- Enrollment
- 60 estimated
- Locations
- University of California, San Francisco, San Francisco, California, United States
- Registry updated
- 2026-08-07
CompletedNCT06835699
Open Label Psilocybin Brain Stimulation and Imaging Pilot Study
Johns Hopkins University
- Conditions
- Healthy Volunteers
- Phase
- Phase 1
- Enrollment
- 10 actual
- Locations
- Johns Hopkins School of Medicine, Baltimore, Maryland, United States
- Registry updated
- 2026-08-07
Not yet recruitingNCT07406828
Single Dose Psilocybin for a Post-surgical Trauma Inpatient Population for Pain, Mood, and Opioid Use Disorder
Trent Emerick
- Conditions
- Pain Management · Postoperative Pain
- Phase
- Phase 1
- Enrollment
- 70 estimated
- Locations
- UPMC Presbyterian, Pittsburgh, Pennsylvania, United States
- Registry updated
- 2026-08-06
RecruitingNCT06233344
An Exploratory Study of Feasibility, Efficacy, and Mechanisms of Mindfulness-Assisted Psychedelic Therapy
University of Southern California
- Conditions
- Mental Health
- Phase
- Phase 2
- Enrollment
- 40 estimated
- Locations
- Univeristy of Southern California Brain and Creativity Institute, Los Angeles, California, United States
- Registry updated
- 2026-08-06
RecruitingNCT06001749
Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced Cancer
Yvan Beaussant, MD, MSci
- Conditions
- Opioid-Related Disorders · Pain Management · Pain Management and Care · Advanced Cancer
- Phase
- Phase 2
- Enrollment
- 15 estimated
- Locations
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Registry updated
- 2026-08-05
RecruitingNCT07118332
Psilocybin as a Treatment for Chronic Pain in Smokers
Yale University
- Conditions
- Smokers With Chronic Pain
- Phase
- Early Phase 1
- Enrollment
- 10 estimated
- Locations
- Department of Veterans Affairs, West Haven, Connecticut, United States
- Registry updated
- 2026-08-03
Not yet recruitingNCT06988319
Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study
Oregon Health and Science University
- Conditions
- Chronic Pelvic Pain
- Phase
- Phase 1
- Enrollment
- 15 estimated
- Locations
- Oregon Health & Science University, Portland, Oregon, United States
- Registry updated
- 2026-08-03
Active, not recruitingNCT07336238
A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and Depression
University of Washington
- Conditions
- Anxiety · Depression · Hematopoietic and Lymphatic System Neoplasm · Metastatic Malignant Solid Neoplasm
- Phase
- Phase 2
- Enrollment
- 18 estimated
- Locations
- Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
- Registry updated
- 2026-07-31
RecruitingNCT06706232
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality
The University of Texas Health Science Center, Houston
- Conditions
- Bipolar II Disorder · Depression, Bipolar · Suicidality
- Phase
- Phase 2
- Enrollment
- 10 estimated
- Locations
- The University of Texas Health Science Center at Houston, Houston, Texas, United States
- Registry updated
- 2026-07-30
RecruitingNCT06200155
TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
M.D. Anderson Cancer Center
- Conditions
- Depression, Anxiety · Psilocybin-Assisted Psychotherapy · Advanced Cancer
- Phase
- Phase 2
- Enrollment
- 30 estimated
- Locations
- MD Anderson Cancer Center, Houston, Texas, United States
- Registry updated
- 2026-07-29
RecruitingNCT06801041
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
M.D. Anderson Cancer Center
- Conditions
- Depression · Anxiety · Cancer
- Phase
- Phase 2
- Enrollment
- 20 estimated
- Locations
- The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
- Registry updated
- 2026-07-29
Active, not recruitingNCT07275970
An Open-Label, Phase 1 Study of the Safety Pharmacokinetic Profile, and Preliminary Efficacy, of Organic Whole Psilocybin-Containing Mushrooms in Patients Suffering From PTSD
Scottsdale Research Institute
- Conditions
- PTSD
- Phase
- Phase 1
- Enrollment
- 24 estimated
- Locations
- Scottsdale Research Institute, Scottsdale, Arizona, United States
- Registry updated
- 2026-07-29
Not yet recruitingNCT07227909
NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy
M.D. Anderson Cancer Center
- Conditions
- Psilocybin · Neuropathy
- Phase
- Phase 2
- Enrollment
- 83 estimated
- Locations
- MD Anderson Cancer Center, Houston, Texas, United States
- Registry updated
- 2026-07-29
RecruitingNCT05866471
Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of Psilocybin
University of Wisconsin, Madison
- Conditions
- Healthy · Psychedelic Experiences · Vagus Nerve Stimulation
- Phase
- Phase 1
- Enrollment
- 108 estimated
- Locations
- University of Wisconsin - Madison, Madison, Wisconsin, United States
- Registry updated
- 2026-07-29
Not yet recruitingNCT07719088
An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in Life
Charles Raison
- Conditions
- Aging · Longevity · Biomarkers of Aging
- Phase
- Phase 1
- Enrollment
- 50 estimated
- Locations
- Vail Health Behavioral Health, Edwards, Colorado, United States
- Registry updated
- 2026-07-24
RecruitingNCT06355414
Psilocybin and Affective Function in Chronic Lower Back Pain Depression
Johns Hopkins University
- Conditions
- Chronic Low-back Pain · Depression
- Phase
- Phase 1
- Enrollment
- 40 estimated
- Locations
- Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
- Registry updated
- 2026-07-24
RecruitingNCT07347405
A Randomized Double-masked Dose-controlled Trial to Assess the Tolerability, Safety, Subjective Experience, and Efficacy of Repeated Administration of Three Different Doses of Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.
Francisco A Moreno
- Conditions
- Obsessive-Compulsive Disorder
- Phase
- Phase 1
- Enrollment
- 30 estimated
- Locations
- The Clinical and Translational Sciences Research Center, Tucson, Arizona, United States
- Registry updated
- 2026-07-23
RecruitingNCT05301608
Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought
Johns Hopkins University
- Conditions
- Healthy
- Phase
- Phase 1 · Phase 2
- Enrollment
- 30 estimated
- Locations
- Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States
- Registry updated
- 2026-07-23
Active, not recruitingNCT06308653
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)
Usona Institute
- Conditions
- Depressive Disorder, Major
- Phase
- Phase 3
- Enrollment
- 238 actual
- Locations
- University of Alabama Clinical Research Unit, Birmingham, Alabama, United States · Preferred Research Partners-NWA, LLC, Fayetteville, Arkansas, United States · Preferred Research Partners, Inc., Little Rock, Arkansas, United States · +26 more
- Registry updated
- 2026-07-23
RecruitingNCT06820723
A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety
Ohio State University
- Conditions
- Depression · Anxiety · Major Depressive Disorder
- Phase
- Phase 2
- Enrollment
- 40 estimated
- Locations
- The Ohio State University Department of Psychiatry, Columbus, Ohio, United States
- Registry updated
- 2026-07-23
RecruitingNCT07610135
PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin Pretreatment
Johns Hopkins University
- Conditions
- Mood (Psychological Function) · Well Being · Mood · Healthy
- Phase
- Phase 1 · Phase 2
- Enrollment
- 20 estimated
- Locations
- Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States
- Registry updated
- 2026-07-21
RecruitingNCT06814522
Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)]
University of California, San Diego
- Conditions
- Burnout · Burnout, Healthcare Workers
- Phase
- Phase 1 · Phase 2
- Enrollment
- 10 estimated
- Locations
- UC San Diego, San Diego, California, United States
- Registry updated
- 2026-07-21
RecruitingNCT07610369
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease
Yale University
- Conditions
- Depression · Parkinson's Disease (PD)
- Phase
- Phase 2
- Enrollment
- 40 estimated
- Locations
- Yale University, New Haven, Connecticut, United States
- Registry updated
- 2026-07-20
RecruitingNCT06067737
Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial
Johns Hopkins University
- Conditions
- Opioid Use Disorder
- Phase
- Phase 2
- Enrollment
- 90 estimated
- Locations
- Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States
- Registry updated
- 2026-07-17
RecruitingNCT06247839
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
Sharmin Ghaznavi
- Conditions
- Major Depressive Disorder
- Phase
- Phase 3
- Enrollment
- 20 estimated
- Locations
- Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts, United States
- Registry updated
- 2026-07-17
Not yet recruitingNCT07306364
Psilocybin in Chronic Low Back Pain: An Integrative Study of Lab-Based Mechanisms and Real-World Physical Therapy Outcomes
Yale University
- Conditions
- Chronic Low Back Pain (CLBP) · Physical Therapy · Psilocybin
- Phase
- Phase 2
- Enrollment
- 45 estimated
- Locations
- Connecticut Mental Health Center, New Haven, Connecticut, United States
- Registry updated
- 2026-07-16
RecruitingNCT06464367
Mechanistic Studies of Psilocybin in Headache Disorders
Yale University
- Conditions
- Migraine
- Phase
- Early Phase 1
- Enrollment
- 50 estimated
- Locations
- VA Connecticut Healthcare System, West Haven, Connecticut, United States
- Registry updated
- 2026-07-13
RecruitingNCT05265546
Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain
University of California, Berkeley
- Conditions
- Perception Disorders
- Phase
- Phase 1
- Enrollment
- 80 estimated
- Locations
- University of California, Berkeley, Berkeley, California, United States
- Registry updated
- 2026-07-10
Not yet recruitingNCT07693153
The Effects of Psilocybin on Social Connectedness
Yale University
- Conditions
- Loneliness · Grief
- Phase
- Phase 1
- Enrollment
- 51 estimated
- Locations
- Connecticut Mental Health Center, New Haven, Connecticut, United States
- Registry updated
- 2026-07-09
TerminatedNCT06624137
Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic Effects
Yale University
- Conditions
- OCD · Major Depressive Disorder (MDD) · Alcohol Use Disorder (AUD) · Healthy Volunteer
- Phase
- Phase not reported
- Enrollment
- 5 actual
- Locations
- Connecticut Mental Health Center, Hamden, Connecticut, United States · West Haven VA Medical Center, West Haven, Connecticut, United States
- Registry updated
- 2026-07-09
RecruitingNCT06810310
Psilocybin: Capturing Brain Mechanisms of Motivation and Neurocognition in Individuals With Opioid Use Disorder
University of Pennsylvania
- Conditions
- Opioid Use Disorder
- Phase
- Phase 2
- Enrollment
- 24 estimated
- Locations
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Registry updated
- 2026-07-09
RecruitingNCT04161066
Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone Formulation
University of Wisconsin, Madison
- Conditions
- Opioid Use Disorder
- Phase
- Phase 1
- Enrollment
- 10 estimated
- Locations
- University of Wisconsin, Madison, Wisconsin, United States
- Registry updated
- 2026-07-07
RecruitingNCT06160284
Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)
Yale University
- Conditions
- Opioid Use Disorder
- Phase
- Phase 1
- Enrollment
- 12 estimated
- Locations
- Yale University, New Haven, Connecticut, United States
- Registry updated
- 2026-07-07
RecruitingNCT07516405
A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older Adults
University of Colorado, Denver
- Conditions
- Healthy Volunteer · Older Adults (65-85 Years)
- Phase
- Phase 1
- Enrollment
- 40 estimated
- Locations
- University of California San Francisco (UCSF) Department of Neurology, San Francisco, California, United States · University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States · Emory University Brain Health Center, Atlanta, Georgia, United States · +3 more
- Registry updated
- 2026-07-06
Not yet recruitingNCT07360301
Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study
University of Wisconsin, Madison
- Conditions
- Well-Being, Psychological · Psychedelic Experiences
- Phase
- Phase 1
- Enrollment
- 120 estimated
- Locations
- University of Wisconsin, Madison, Wisconsin, United States
- Registry updated
- 2026-07-02
RecruitingNCT06902974
A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)
Sunstone Medical
- Conditions
- Post Traumatic Stress Disorder · PTSD
- Phase
- Phase 2
- Enrollment
- 70 estimated
- Locations
- Sunstone Medical, PC, Rockville, Maryland, United States
- Registry updated
- 2026-07-01
RecruitingNCT05452772
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder
Johns Hopkins University
- Conditions
- Tobacco Use Disorder
- Phase
- Phase 2
- Enrollment
- 66 estimated
- Locations
- University of Alabama at Birmingham, Birmingham, Alabama, United States · Johns Hopkins University School of Medicine, Baltimore, Maryland, United States · New York University, New York, New York, United States
- Registry updated
- 2026-06-29
RecruitingNCT07104916
A Pilot Mechanistic RCT of Psilocybin With Mindfulness-based Therapy vs Support for Posttraumatic Stress Disorder (PTSD)
Anthony P King
- Conditions
- Post Traumatic Stress Disorder · Depression - Major Depressive Disorder
- Phase
- Phase 2
- Enrollment
- 30 estimated
- Locations
- The Ohio State University Medical Center, Columbus, Ohio, United States
- Registry updated
- 2026-06-25
RecruitingNCT07565493
Psilocybin Administration With 5-HT1a Blockade
Johns Hopkins University
- Conditions
- Psychedelic Effects in Healthy Volunteers
- Phase
- Early Phase 1
- Enrollment
- 18 estimated
- Locations
- Center for Psychedelics and Consciousness Research, Baltimore, Maryland, United States
- Registry updated
- 2026-06-25
Not yet recruitingNCT07449351
Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot Study
Yale University
- Conditions
- Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI
- Phase
- Early Phase 1
- Enrollment
- 20 estimated
- Locations
- Olin Neuropsychiatry Research Center, Hartford, Connecticut, United States
- Registry updated
- 2026-06-23
RecruitingNCT06724289
Psilocybin-Assisted Therapy for Prolonged Grief
University of Virginia
- Conditions
- Prolonged Grief Disorder
- Phase
- Early Phase 1
- Enrollment
- 12 estimated
- Locations
- University of Virginia, Charlottesville, Virginia, United States
- Registry updated
- 2026-06-23
Not yet recruitingNCT06827054
Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring Opioids
Roswell Park Cancer Institute
- Conditions
- Hematopoietic and Lymphatic System Neoplasm · Malignant Solid Neoplasm
- Phase
- Phase 2
- Enrollment
- 20 estimated
- Locations
- Roswell Park Cancer Institute, Buffalo, New York, United States
- Registry updated
- 2026-06-22
Active, not recruitingNCT06407635
Psilocybin for PTSD With or Without Psychotherapy: A Pilot Study of Safety and Efficacy
Johns Hopkins University
- Conditions
- Post Traumatic Stress Disorder
- Phase
- Phase 1
- Enrollment
- 20 estimated
- Locations
- Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States
- Registry updated
- 2026-06-22
Not yet recruitingNCT07079852
The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function
Manoj Doss
- Conditions
- Healthy
- Phase
- Phase 1 · Phase 2
- Enrollment
- 48 estimated
- Locations
- The University of Texas at Austin Dell Medical School, Austin, Texas, United States
- Registry updated
- 2026-06-15
Not yet recruitingNCT07296094
Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized Trial
Brigham and Women's Hospital
- Conditions
- Alcohol Use Disorder
- Phase
- Phase 2
- Enrollment
- 36 estimated
- Locations
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- Registry updated
- 2026-06-15
RecruitingNCT07386730
A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's Disease
Jennifer Mitchell
- Conditions
- Anhedonia in Healthy Volunteers · Older Adults (50-90 Years)
- Phase
- Phase 1
- Enrollment
- 80 estimated
- Locations
- University of California San Francisco, Sandler Neuroscience Building, San Francisco, California, United States
- Registry updated
- 2026-06-08
Active, not recruitingNCT05698511
Multivariate Neural and Physiological Correlates of Psychedelic Sub-states: a Within-subjects, Healthy Volunteer Study With Experience-sampling
Robin Carhart-Harris, PhD, MA
- Conditions
- Psychedelic Experiences · Neuroimaging · Healthy Volunteers
- Phase
- Phase 1
- Enrollment
- 12 estimated
- Locations
- University of California, San Francisco, San Francisco, California, United States
- Registry updated
- 2026-06-05
Not yet recruitingNCT07226232
A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in Veterans
VA Office of Research and Development
- Conditions
- Major Depression
- Phase
- Phase 3
- Enrollment
- 240 estimated
- Locations
- Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama, United States · Tuscaloosa VA Medical Center, Tuscaloosa, AL, Tuscaloosa, Alabama, United States · VA Portland Health Care System, Portland, OR, Portland, Oregon, United States · +2 more
- Registry updated
- 2026-06-05
Active, not recruitingNCT05370911
Effects of Repeated Dosing of Psilocybin on Obsessive-Compulsive Disorder: A Randomized, Waitlist-Controlled Study
Yale University
- Conditions
- Obsessive-Compulsive Disorder
- Phase
- Phase 1
- Enrollment
- 28 actual
- Locations
- Enact Research Collaborative (40 Temple St, 4th Floor), New Haven, Connecticut, United States · Yale Program for Psychedelic Research, New Haven, Connecticut, United States
- Registry updated
- 2026-06-04
RecruitingNCT06626139
2 x 2 Factorial, Double-blind, Randomized Trial of 'Set and Setting': a Translational Study in Healthy Volunteers
Robin Carhart-Harris, PhD, MA
- Conditions
- Healthy Participants With Lower-than-average Mental Well-being
- Phase
- Phase 2
- Enrollment
- 120 estimated
- Locations
- UCSF Mission Bay, San Francisco, California, United States
- Registry updated
- 2026-06-04
Not yet recruitingNCT07607938
Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual Anhedonia
NYU Langone Health
- Conditions
- Anhedonia · Emotional Blunting
- Phase
- Phase 1
- Enrollment
- 90 estimated
- Locations
- NYU Langone Health, New York, New York, United States
- Registry updated
- 2026-05-27
Not yet recruitingNCT07332143
The Safety and Acceptability of Psilocybin With Support and With Massed Prolonged Exposure Therapy for PTSD
Emory University
- Conditions
- PTSD
- Phase
- Phase 2
- Enrollment
- 150 estimated
- Locations
- Emory University Hospital, Atlanta, Georgia, United States
- Registry updated
- 2026-05-26
CompletedNCT06230757
Effects of Psilocybin With Psychological Support on Anhedonia in Treatment-resistant Depression: a Randomized Controlled Pilot Trial
University of Colorado, Denver
- Conditions
- Major Depressive Disorder · Anhedonia · Treatment Resistant Depression
- Phase
- Phase 2
- Enrollment
- 20 actual
- Locations
- University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
- Registry updated
- 2026-05-22
RecruitingNCT07506395
Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder
University of New Mexico
- Conditions
- PTSD
- Phase
- Phase 1
- Enrollment
- 36 estimated
- Locations
- Interdisciplinary Substance Use and Brain Injury (ISUBI), Albuquerque, New Mexico, United States
- Registry updated
- 2026-05-22
Not yet recruitingNCT07582120
A Pilot Mechanistic Study of Psilocybin-Assisted Therapy as a Treatment for Depression
Washington University School of Medicine
- Conditions
- Depression
- Phase
- Phase 2
- Enrollment
- 50 estimated
- Locations
- Washington University School of Medicine, St Louis, Missouri, United States
- Registry updated
- 2026-05-20
CompletedNCT05227612
Psilocybin-assisted Cognitive Behavioral Therapy for Depression
University of California, Los Angeles
- Conditions
- Major Depressive Disorder
- Phase
- Phase 1
- Enrollment
- 16 actual
- Locations
- UCLA Semel Institute, Los Angeles, California, United States
- Registry updated
- 2026-05-19
CompletedNCT02037126
Psilocybin-facilitated Treatment for Cocaine Use
University of Alabama at Birmingham
- Conditions
- Cocaine-Related Disorders
- Phase
- Phase 2
- Enrollment
- 40 actual
- Locations
- UAB Outpatient Clinical Research Unit, Birmingham, Alabama, United States
- Registry updated
- 2026-05-18
RecruitingNCT07216404
Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY)
Alan Davis
- Conditions
- Lung Non-Small Cell Carcinoma · Unipolar Depression
- Phase
- Phase 2
- Enrollment
- 10 estimated
- Locations
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- Registry updated
- 2026-05-14
Not yet recruitingNCT06992999
Psilocybin for Treatment of Obsessive Compulsive Disorder
Francisco A Moreno
- Conditions
- Obsessive - Compulsive Disorder
- Phase
- Phase 1 · Phase 2
- Enrollment
- 20 estimated
- Locations
- University of Arizona-Tucson, Tucson, Arizona, United States
- Registry updated
- 2026-05-12
TerminatedNCT05322954
Safety and Feasibility of Psilocybin in Methamphetamine Use Disorder in a Community-Based Sample
University of Wisconsin, Madison
- Conditions
- Methamphetamine Use Disorder · Substance-Related Disorders · Chemically-Induced Disorders · Substance Use Disorders
- Phase
- Phase 1
- Enrollment
- 5 actual
- Locations
- University of Wisconsin, Madison, Wisconsin, United States
- Registry updated
- 2026-05-12
Active, not recruitingNCT05947383
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With Cancer
Sunstone Medical
- Conditions
- Cancer · Major Depressive Disorder
- Phase
- Phase 2
- Enrollment
- 56 estimated
- Locations
- Sunstone Medical, PC, Rockville, Maryland, United States
- Registry updated
- 2026-05-06
Active, not recruitingNCT06303739
Induction Protocol for Psilocybin-Assisted Therapy in Treatment-Resistant Depression (TRD): A Pilot Study
University of North Carolina, Chapel Hill
- Conditions
- Refractory Depression · Treatment Resistant Depression
- Phase
- Phase 3
- Enrollment
- 20 actual
- Locations
- UNC Chapel Hill Medical Center, Chapel Hill, North Carolina, United States
- Registry updated
- 2026-05-06
Not yet recruitingNCT07479550
A Phase 2 Randomized Study Examining the Safety, Feasibility, and Effectiveness of Masking Psilocybin Therapy With General Anesthesia in Major Depressive Disorder
Stanford University
- Conditions
- Major Depression
- Phase
- Phase 2
- Enrollment
- 10 estimated
- Locations
- Stanford University, Stanford, California, United States
- Registry updated
- 2026-05-06
Active, not recruitingNCT05220046
An Exploratory Pilot Study of Palliadelic Treatment to Reduce Psychological Distress in People With Pancreatobiliary and Other Advanced Gastrointestinal Cancers
University of Nebraska
- Conditions
- Pancreas Cancer · Biliary Tract Cancer · Psychological Distress · Gastrointestinal Cancer
- Phase
- Phase 1
- Enrollment
- 24 estimated
- Locations
- University of Nebraska Medical Center, Omaha, Nebraska, United States
- Registry updated
- 2026-05-06
TerminatedNCT04353921
A One-Year Observational Follow-up Study of Participants With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-Control
Usona Institute
- Conditions
- Major Depressive Disorder
- Phase
- Phase not reported
- Enrollment
- 26 actual
- Locations
- Innovative Clinical Research, Inc. (formerly Segal Trials), Lauderhill, Florida, United States
- Registry updated
- 2026-05-04
RecruitingNCT07251491
Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord Injury
James J. Peters Veterans Affairs Medical Center
- Conditions
- Spinal Cord Injury · Depression - Major Depressive Disorder · Veteran
- Phase
- Phase 1 · Phase 2
- Enrollment
- 30 estimated
- Locations
- James J. Peters Department of Veterans Affairs Medical Center, The Bronx, New York, United States
- Registry updated
- 2026-05-04
Not yet recruitingNCT07566104
Group Psilocybin-assisted Cognitive Behavioral Therapy for Major Depressive Disorder
University of California, Los Angeles
- Conditions
- Depression - Major Depressive Disorder · Psilocybin · Cognitive Behavioral Therapy
- Phase
- Phase 2
- Enrollment
- 30 estimated
- Locations
- UCLA Semel Institute, Los Angeles, California, United States
- Registry updated
- 2026-05-04
Active, not recruitingNCT05351541
A Double-blind, Randomized Trial Examining the Preliminary Efficacy of Psilocybin Therapy for People With Chronic Low Back Pain
Joshua Woolley, MD, PhD
- Conditions
- Chronic Low-back Pain
- Phase
- Phase 1 · Phase 2
- Enrollment
- 30 estimated
- Locations
- University of California San Francisco, San Francisco, California, United States
- Registry updated
- 2026-04-29
Active, not recruitingNCT04982796
Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder
Portland VA Research Foundation, Inc
- Conditions
- Amphetamine-Related Disorders
- Phase
- Phase 1 · Phase 2
- Enrollment
- 30 estimated
- Locations
- Portland VA Health Care System, Vancouver, Washington, United States
- Registry updated
- 2026-04-22
CompletedNCT03866174
A Randomized, Double-Blind Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD)
Usona Institute
- Conditions
- Depressive Disorder, Major
- Phase
- Phase 2
- Enrollment
- 347 actual
- Locations
- University of California, San Francisco, San Francisco, California, United States · Pacific Neuroscience Institute, Santa Monica, California, United States · Yale University, New Haven, Connecticut, United States · +8 more
- Registry updated
- 2026-04-22
RecruitingNCT06430541
Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence in Patients Diagnosed With Early-stage Breast Cancer and Ovarian Cancer in Remission
University of Colorado, Denver
- Conditions
- Breast Cancer · Ovarian Cancer
- Phase
- Phase 1
- Enrollment
- 20 estimated
- Locations
- Outpatient CTRC, Aurora, Colorado, United States · University of Colorado Cancer Center, Aurora, Colorado, United States
- Registry updated
- 2026-04-21
SuspendedNCT06102434
Safety Profile of 25 mg Psilocybin in Individuals With Cocaine Use Disorder
University of California, Los Angeles
- Conditions
- Cocaine Use Disorder
- Phase
- Early Phase 1
- Enrollment
- 10 estimated
- Locations
- University of California, Los Angeles, Los Angeles, California, United States
- Registry updated
- 2026-04-07
RecruitingNCT06692192
Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study)
University of Wisconsin, Madison
- Conditions
- Psilocybin
- Phase
- Phase 1
- Enrollment
- 60 estimated
- Locations
- UW School of Medicine and Public Health, Madison, Wisconsin, United States
- Registry updated
- 2026-04-03
Active, not recruitingNCT05546658
Effects of Psilocybin in Obsessive Compulsive Disorder
Johns Hopkins University
- Conditions
- Obsessive-Compulsive Disorder
- Phase
- Early Phase 1
- Enrollment
- 35 actual
- Locations
- Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
- Registry updated
- 2026-04-02
Not yet recruitingNCT07499583
Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder
Indiana University
- Conditions
- Treatment Resistant Depression · Substance Use Disorders
- Phase
- Phase 1 · Phase 2
- Enrollment
- 50 estimated
- Locations
- Goodman Hall, Dept of Psychiatry, Indiana University, Indianapolis, Indiana, United States · The Stark Neuroscience Building (Goodman Hall), Indianapolis, Indiana, United States
- Registry updated
- 2026-03-30
RecruitingNCT06660381
Pilot Study of Psilocybin-assisted Treatment for Cannabis Use Disorder
Johns Hopkins University
- Conditions
- Cannabis Use Disorder
- Phase
- Phase 1
- Enrollment
- 12 estimated
- Locations
- Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States
- Registry updated
- 2026-03-18
RecruitingNCT04123314
Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease
Johns Hopkins University
- Conditions
- Depressive Symptoms · Depression · Alzheimer Disease · Mild Cognitive Impairment
- Phase
- Early Phase 1
- Enrollment
- 20 estimated
- Locations
- Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States
- Registry updated
- 2026-03-16
Active, not recruitingNCT04620759
Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder
Johns Hopkins University
- Conditions
- Major Depressive Disorder · Alcohol Use Disorder
- Phase
- Phase 2
- Enrollment
- 90 estimated
- Locations
- Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States
- Registry updated
- 2026-03-13
WithdrawnNCT05227742
Exploratory Study of the Effects of Low-Dose Psilocybin on Sensory Processing, Neurophysiological Arousal, and Emotional Health
University of Alabama at Birmingham
- Conditions
- Demoralization
- Phase
- Early Phase 1
- Enrollment
- 0 actual
- Locations
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Registry updated
- 2026-03-11
RecruitingNCT05068791
Psilocybin-facilitated Treatment for Chronic Pain
University of Alabama at Birmingham
- Conditions
- Fibromyalgia, Primary
- Phase
- Early Phase 1
- Enrollment
- 30 estimated
- Locations
- UAB Beacon Tower, Birmingham, Alabama, United States
- Registry updated
- 2026-03-11
RecruitingNCT06442423
Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study
Yale University
- Conditions
- Transdiagnostic · Depression - Major Depressive Disorder · Anxiety · PTSD Symptoms
- Phase
- Phase 1
- Enrollment
- 50 estimated
- Locations
- Connecticut Mental Health Center - Yale School of Medicine, New Haven, Connecticut, United States
- Registry updated
- 2026-03-11
Not yet recruitingNCT06760533
Pilot Proof of Concept Study Evaluating the Potential Psilocybin Assisted Psychotherapy (PAP) as a Therapeutic Tool for Patients Suffering From Severe Irritable Bowel Syndrome.
NYU Langone Health
- Conditions
- IBS - Irritable Bowel Syndrome
- Phase
- Early Phase 1
- Enrollment
- 10 estimated
- Locations
- NYU Langone Health, New York, New York, United States
- Registry updated
- 2026-03-05
Active, not recruitingNCT05554094
Examining the Safety and Clinical Efficacy of Psilocybin Therapy for Veterans With PTSD: An Open-Label Proof-of-Concept Trial
Ohio State University
- Conditions
- PTSD · Stress Disorders, Traumatic · Stress Disorders, Post-Traumatic · Trauma and Stressor Related Disorders
- Phase
- Phase 2
- Enrollment
- 15 estimated
- Locations
- Ohio State University Department of Psychiatry and Behavioral Health at the Davis Medical Research Center, Columbus, Ohio, United States
- Registry updated
- 2026-03-04
RecruitingNCT06399263
Study of Psilocybin for Anorexia in Young Adults
Marissa Raymond-Flesch, MD, MPH
- Conditions
- Anorexia Nervosa
- Phase
- Phase 2
- Enrollment
- 40 estimated
- Locations
- University of California, San Francisco, San Francisco, California, United States
- Registry updated
- 2026-03-03
WithdrawnNCT06005662
Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial
Johns Hopkins University
- Conditions
- Opioid Use Disorder
- Phase
- Phase 2
- Enrollment
- 0 actual
- Locations
- Johns Hopkins University, Baltimore, Maryland, United States
- Registry updated
- 2026-02-23
RecruitingNCT06450210
Safety for Home Administration of Microdose Psilocybin Use
Johns Hopkins University
- Conditions
- Psychedelic Experiences
- Phase
- Phase 1
- Enrollment
- 20 estimated
- Locations
- 5510 Nathan Shock Drive, Baltimore, Maryland, United States
- Registry updated
- 2026-02-23
RecruitingNCT06772753
Investigation of Psychedelic Effects in Psychoactive Substances
Johns Hopkins University
- Conditions
- Psychedelic Effects in Healthy Volunteers
- Phase
- Phase 1
- Enrollment
- 50 estimated
- Locations
- Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States
- Registry updated
- 2026-02-23
CompletedNCT04950608
Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care - PATH Study
Yvan Beaussant, MD, MSci
- Conditions
- Hospice · Psilocybin · Demoralization · Terminal Illness
- Phase
- Phase 2
- Enrollment
- 15 actual
- Locations
- Care Dimensions, Danvers, Massachusetts, United States
- Registry updated
- 2026-02-17
RecruitingNCT07053917
Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability
Johns Hopkins University
- Conditions
- Stroke · Chronic Stroke · Intracerebral Haemorrhage · Intracerebral Haemorrhage (ICH)
- Phase
- Phase 1
- Enrollment
- 20 estimated
- Locations
- Johns Hopkins, Baltimore, Maryland, United States
- Registry updated
- 2026-02-13
RecruitingNCT07281352
Psilocybin-Assisted Cognitive Behavioral Therapy for Depression
University of California, Los Angeles
- Conditions
- Major Depressive Diorder
- Phase
- Phase 1 · Phase 2
- Enrollment
- 50 estimated
- Locations
- UCLA Semel Institute, Los Angeles, California, United States
- Registry updated
- 2026-02-12
Active, not recruitingNCT06206265
A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Oral Psilocybin (TRP-8802) Administration in Concert With Psychotherapy Among Adult Patients With Irritable Bowel Syndrome: A Randomized Delayed Treatment Control Design
TRYP Therapeutics
- Conditions
- Irritable Bowel Syndrome
- Phase
- Phase 2
- Enrollment
- 14 actual
- Locations
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Registry updated
- 2026-02-05
RecruitingNCT06796062
A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone Treatment
NYU Langone Health
- Conditions
- Opioid Use Disorder
- Phase
- Phase 2
- Enrollment
- 480 estimated
- Locations
- Duke City Recovery Toolbox, Albuquerque, New Mexico, United States · University of New Mexico, Albuquerque, New Mexico, United States · StartCare, Brooklyn, New York, United States · +2 more
- Registry updated
- 2026-01-23
RecruitingNCT06888128
The STARLIGHT Protocol: State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma
Baylor College of Medicine
- Conditions
- PTSD
- Phase
- Phase 2
- Enrollment
- 15 estimated
- Locations
- Baylor College of Medicine, Houston, Texas, United States
- Registry updated
- 2026-01-22
Active, not recruitingNCT05711940
A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression
COMPASS Pathways
- Conditions
- Treatment Resistant Depression
- Phase
- Phase 3
- Enrollment
- 572 actual
- Locations
- Lighthouse Psychiatry Scottsdale, Gilbert, Arizona, United States · Clinical Innovations, Inc., Bellflower, California, United States · M3 Wake Research, Encino, California, United States · +113 more
- Registry updated
- 2026-01-12
RecruitingNCT06656702
Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis
Johns Hopkins University
- Conditions
- Amyotrophic Lateral Sclerosis
- Phase
- Early Phase 1
- Enrollment
- 24 estimated
- Locations
- Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States
- Registry updated
- 2026-01-12
CompletedNCT05224336
Behavioral and Neural Mechanisms Supporting Psilocybin-assisted Therapy for Phantom Limb Pain
University of California, San Diego
- Conditions
- Phantom Limb Pain
- Phase
- Phase 1
- Enrollment
- 10 actual
- Locations
- University of California, San Diego, San Diego, California, United States
- Registry updated
- 2026-01-09
CompletedNCT05220410
The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation
Sheppard Pratt Health System
- Conditions
- Treatment Resistant Depression · Suicidal Ideation
- Phase
- Phase 2
- Enrollment
- 20 actual
- Locations
- Sheppard Pratt Health System, Baltimore, Maryland, United States
- Registry updated
- 2025-12-24
CompletedNCT05399498
An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality Disorder
University of Chicago
- Conditions
- Borderline Personality Disorder · Major Depressive Disorder
- Phase
- Phase 2
- Enrollment
- 9 actual
- Locations
- University of Chicago, Chicago, Illinois, United States
- Registry updated
- 2025-12-23
Not yet recruitingNCT07296328
Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter
NYU Langone Health
- Conditions
- Stuttering
- Phase
- Phase 2
- Enrollment
- 25 estimated
- Locations
- NYU Langone Health, New York, New York, United States
- Registry updated
- 2025-12-22
Active, not recruitingNCT05624268
A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant Depression
COMPASS Pathways
- Conditions
- Treatment Resistant Depression
- Phase
- Phase 3
- Enrollment
- 255 estimated
- Locations
- University of Arizona College of Medicine - Tuscon, Tucson, Arizona, United States · ProScience Research Group, Culver City, California, United States · Collaborative Neuroscience Network, LLC, Garden Grove, California, United States · +37 more
- Registry updated
- 2025-12-18
RecruitingNCT05398484
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced Cancer
NYU Langone Health
- Conditions
- Advanced Cancer
- Phase
- Phase 2 · Phase 3
- Enrollment
- 200 estimated
- Locations
- University of Colorado Anschutz Medical campus (CU AMC), Aurora, Colorado, United States · NYU Langone Health, New York, New York, United States
- Registry updated
- 2025-12-04
RecruitingNCT06405607
Psilocybin vs Ketamine for Alcohol Use Disorder
University of Iowa
- Conditions
- Alcohol Use Disorder · Alcohol Dependence · Alcohol Abuse
- Phase
- Phase 2
- Enrollment
- 80 estimated
- Locations
- University of Iowa Health Care, Iowa City, Iowa, United States
- Registry updated
- 2025-11-28
RecruitingNCT06132178
Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder
University of Texas at Austin
- Conditions
- Treatment Resistant Depression · MDD · Major Depressive Disorder · Recurrent Depression
- Phase
- Phase 2
- Enrollment
- 100 estimated
- Locations
- Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, Austin, Texas, United States
- Registry updated
- 2025-11-26
RecruitingNCT05403086
Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC): A Multicenter Triple-blind Phase 2 Randomized Controlled Trial of Psilocybin Therapy for Demoralized Adults Near the End of Life
Charles S. Grob, M.D.
- Conditions
- Demoralization
- Phase
- Phase 2
- Enrollment
- 100 estimated
- Locations
- Marin Cancer Care, Greenbrae, California, United States · University of California, Los Angeles, Los Angeles, California, United States · University of San Francisco, San Francisco, California, United States · +2 more
- Registry updated
- 2025-11-25
Active, not recruitingNCT05421065
Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder
Peggy C Nopoulos
- Conditions
- Alcohol Use Disorder
- Phase
- Phase 2
- Enrollment
- 20 estimated
- Locations
- University of Iowa, Iowa City, Iowa, United States
- Registry updated
- 2025-11-17
Active, not recruitingNCT03554174
Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder
Yale University
- Conditions
- Major Depressive Disorder
- Phase
- Phase 1
- Enrollment
- 18 estimated
- Locations
- VA Connecticut Healthcare System, West Haven Campus, West Haven, Connecticut, United States
- Registry updated
- 2025-11-05
CompletedNCT05847686
A Phase 1/2 Study of a Group Model of Psilocybin-Assisted Therapy for Cancer-Related Anxiety in Patients With Metastatic Cancer
University of Washington
- Conditions
- Hematopoietic and Lymphatic System Neoplasm · Metastatic Malignant Solid Neoplasm
- Phase
- Phase 1 · Phase 2
- Enrollment
- 55 actual
- Locations
- Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
- Registry updated
- 2025-11-05
CompletedNCT04501653
Precision Functional Brain Mapping to Understand the Mechanisms of Psilocybin
Washington University School of Medicine
- Conditions
- Psilocybin
- Phase
- Early Phase 1
- Enrollment
- 11 actual
- Locations
- Washington University, St Louis, Missouri, United States
- Registry updated
- 2025-10-31
RecruitingNCT06786325
A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)?
Anna Rose Childress, Ph.D.
- Conditions
- Opioid Use Disorder
- Phase
- Phase 2
- Enrollment
- 36 estimated
- Locations
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Registry updated
- 2025-10-29
RecruitingNCT06367738
Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults
University of California, Berkeley
- Conditions
- Aging
- Phase
- Phase 1
- Enrollment
- 40 estimated
- Locations
- University of California, Berkeley, Berkeley, California, United States
- Registry updated
- 2025-10-21
CompletedNCT06644170
A Phase 1 Study of a Second Psilocybin Group Retreat for Partial Responders With Anxiety Associated With Metastatic Cancer
University of Washington
- Conditions
- Hematopoietic and Lymphatic System Neoplasm · Metastatic Malignant Solid Neoplasm
- Phase
- Phase 1
- Enrollment
- 15 actual
- Locations
- Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
- Registry updated
- 2025-10-14
RecruitingNCT06899594
A Pilot Study in North Louisiana to Assess the Tolerability of Psilocybin as Well as Its Capacity to Promote Abstinence From Methamphetamine
Kevin Murnane
- Conditions
- Methamphetamine Use Disorder
- Phase
- Early Phase 1
- Enrollment
- 20 estimated
- Locations
- LSU Health Shreveport, Shreveport, Louisiana, United States
- Registry updated
- 2025-10-07
RecruitingNCT06989957
Psilocybin and MDMA for Post-traumatic Stress Disorder (PTSD)
Johns Hopkins University
- Conditions
- Posttraumatic Stress Disorder
- Phase
- Phase 1
- Enrollment
- 40 estimated
- Locations
- Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States
- Registry updated
- 2025-10-01
Active, not recruitingNCT07189988
Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism
Healing Advocacy Fund
- Conditions
- Alcohol Use Disorder
- Phase
- Phase not reported
- Enrollment
- 20 actual
- Locations
- Innertrek Patient Service Center, Portland, Oregon, United States
- Registry updated
- 2025-09-24
Enrolling by invitationNCT07180108
PRoMiSS: Psilocybin and the Role of Music in Set and Setting
Johns Hopkins University
- Conditions
- Psilocybin · Music Intervention
- Phase
- Phase 1
- Enrollment
- 100 estimated
- Locations
- Center for Psychedelics and Consciousness Research in the Behavioral Biology Research Center, Baltimore, Maryland, United States
- Registry updated
- 2025-09-18
RecruitingNCT06899165
Processing Intergenerational Trauma With Psilocybin-Assisted Therapy
Rachel Yehuda
- Conditions
- Psychological Stress · Depression · Anxiety
- Phase
- Phase 2
- Enrollment
- 100 estimated
- Locations
- The Parsons Research Center for Psychedelic Healing, New York, New York, United States
- Registry updated
- 2025-09-08
RecruitingNCT06853912
A Phase 2 Single-site, Double-blind, Placebo-controlled, Randomized Clinical Trial With an Open-label Extension Phase to Examine the Safety, Subjective Experiences, Acute Effects, and Suitability of Psilocybin Combined With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD)
Nathan Brashares Sackett
- Conditions
- Alcohol Use Disorder (AUD) · PTSD
- Phase
- Phase 2
- Enrollment
- 40 estimated
- Locations
- University of Washington Center for Novel Therapeutics in Addiction Psychiatry, Seattle, Washington, United States
- Registry updated
- 2025-08-28
CompletedNCT05305105
Effects of Psilocybin in Post-Treatment Lyme Disease
Johns Hopkins University
- Conditions
- Post-Treatment Lyme Disease · Chronic Lyme Disease · Lyme Disease, Chronic
- Phase
- Phase 1
- Enrollment
- 20 actual
- Locations
- Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States
- Registry updated
- 2025-08-20
Active, not recruitingNCT05733546
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
COMPASS Pathways
- Conditions
- Major Depressive Disorder
- Phase
- Phase 2
- Enrollment
- 102 actual
- Locations
- Kadima Neuropsychiatry Institute, La Jolla, California, United States · Clinical Neuroscience Solutions Inc, Jacksonville, Florida, United States · Sunstone Therapies, Rockville, Maryland, United States · +2 more
- Registry updated
- 2025-08-19
CompletedNCT05506982
The Safety, Feasibility, and Acceptability of Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain (P-PC)
Emory University
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm · Malignant Solid Neoplasm
- Phase
- Phase 1
- Enrollment
- 11 actual
- Locations
- Emory University/Winship Cancer Institute, Atlanta, Georgia, United States · Brain Health Center at Executive Park, Atlanta, Georgia, United States
- Registry updated
- 2025-07-23
TerminatedNCT04424225
Visual Surround Suppression and Perceptual Expectation Under Psilocybin
University of Minnesota
- Conditions
- Perception Disturbance · Visual Suppression · Psychedelic Experiences
- Phase
- Phase 1
- Enrollment
- 10 actual
- Locations
- University of Minnesota, Minneapolis, Minnesota, United States
- Registry updated
- 2025-06-27
CompletedNCT05312151
The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
COMPASS Pathways
- Conditions
- Post Traumatic Stress Disorder
- Phase
- Phase 2
- Enrollment
- 22 actual
- Locations
- Sunstone Therapies, Rockville, Maryland, United States · Icahn School of Medicine at Mount Sinai, New York, New York, United States · Kings College London, Institute of Psychiatry, Psychology and Neurology, London, United Kingdom
- Registry updated
- 2025-06-13
Active, not recruitingNCT05317689
Comparison of the Effects of PEX20 (Oral Psilocin), PEX30 (Sublingual Psilocin), and PEX10 (Oral Psilocybin) in Healthy Adults
University of California, San Francisco
- Conditions
- Healthy
- Phase
- Phase 1
- Enrollment
- 20 estimated
- Locations
- University of California, San Francisco, San Francisco, California, United States
- Registry updated
- 2025-06-10
Enrolling by invitationNCT06919640
Psilocybin With Intracranial Neural Sensing
Joshua Woolley, MD, PhD
- Conditions
- Chronic Pain
- Phase
- Phase 1
- Enrollment
- 20 estimated
- Locations
- University of California, San Francisco, San Francisco, California, United States
- Registry updated
- 2025-06-06
CompletedNCT06372197
Low-Income Group Psilocybin Assisted Therapy for Depression: A Feasibility Study
Matthew Hicks
- Conditions
- Depression
- Phase
- Not applicable
- Enrollment
- 20 actual
- Locations
- National University of Natural Medicine, Portland, Oregon, United States
- Registry updated
- 2025-06-05
WithdrawnNCT06560658
Optimizing Microdosing and Meditation
National University of Natural Medicine
- Conditions
- Meditation · Microdosing
- Phase
- Not applicable
- Enrollment
- 0 actual
- Locations
- National University of Natural Medicine, Portland, Oregon, United States
- Registry updated
- 2025-06-05
CompletedNCT01943994
Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study
Johns Hopkins University
- Conditions
- Nicotine Dependence
- Phase
- Not applicable
- Enrollment
- 82 actual
- Locations
- Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States · Neuroimaging Research Branch, NIDA-IRP, Baltimore, Maryland, United States
- Registry updated
- 2025-05-25
RecruitingNCT06512194
An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study)
Charles Raison
- Conditions
- Depression
- Phase
- Phase 2
- Enrollment
- 141 estimated
- Locations
- Vail Health Behavioral Health, Edwards, Colorado, United States
- Registry updated
- 2025-05-23
CompletedNCT05592379
Consciousness and Psilocybin Effects on Well-Being (The CoPE Study): Pilot Phase
University of Wisconsin, Madison
- Conditions
- Healthy · Psychedelic Experiences · Sleep
- Phase
- Phase 1
- Enrollment
- 6 actual
- Locations
- University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
- Registry updated
- 2025-05-16
RecruitingNCT06592833
Investigating the Role of Serotonin in the Mechanism of Action of Psilocybin in Patients With Major Depressive Disorder
Icahn School of Medicine at Mount Sinai
- Conditions
- Major Depressive Disorder
- Phase
- Phase 2
- Enrollment
- 60 estimated
- Locations
- Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research, New York, New York, United States
- Registry updated
- 2025-05-14
CompletedNCT05128162
A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Psilocybin Administration in Concert With Psychotherapy Among Adult Patients With Fibromyalgia
Kevin Boehnke
- Conditions
- Fibromyalgia
- Phase
- Phase 2
- Enrollment
- 17 actual
- Locations
- Chronic Pain and Fatigue Research Center, Ann Arbor, Michigan, United States
- Registry updated
- 2025-04-16
CompletedNCT05163496
A Randomized, Placebo-controlled Trial of Psychedelic-assisted Psychotherapy With Single Dose Psilocybin for Frontline Clinicians Experiencing COVID-related Symptoms of Depression and Burnout
University of Washington
- Conditions
- Burnout, Caregiver · Burnout, Professional · COVID-19 · Depression
- Phase
- Phase 3
- Enrollment
- 30 actual
- Locations
- University of Washington, Seattle, Washington, United States
- Registry updated
- 2025-03-18
CompletedNCT00302744
Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Conditions
- Anxiety
- Phase
- Phase 1 · Phase 2
- Enrollment
- 12 actual
- Locations
- Harbor-UCLA Medical Center, Torrance, California, United States
- Registry updated
- 2025-03-13
CompletedNCT04932434
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study
Joshua Woolley, MD, PhD
- Conditions
- Parkinson Disease · Depression · Anxiety
- Phase
- Phase 2
- Enrollment
- 12 actual
- Locations
- University of California, San Francisco, San Francisco, California, United States
- Registry updated
- 2025-01-01
CompletedNCT05481736
Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study
COMPASS Pathways
- Conditions
- Anorexia Nervosa
- Phase
- Phase 2
- Enrollment
- 32 actual
- Locations
- Altman Clinical and Translational Research Institute, San Diego, California, United States · Sheppard Pratt Health System, Baltimore, Maryland, United States · Dell Medical School, Austin, Texas, United States · +2 more
- Registry updated
- 2024-12-04
CompletedNCT03356483
Psilocybin Treatment in Obsessive-Compulsive Disorder: a Preliminary Efficacy Study and Exploratory Investigation of Neural Correlates.
Yale University
- Conditions
- Obsessive-Compulsive Disorder
- Phase
- Phase 1
- Enrollment
- 31 actual
- Locations
- Connecticut Mental Health Center, New Haven, Connecticut, United States
- Registry updated
- 2024-11-20
CompletedNCT05035927
A Phase 2a Safety and Feasibility Study Evaluating Psilocybin (TRP-8802) Administration in Concert With Psychotherapy in the Treatment of Binge Eating Disorder
TRYP Therapeutics
- Conditions
- Binge Eating Disorder
- Phase
- Phase 2
- Enrollment
- 5 actual
- Locations
- University of Florida, Gainesville, Florida, United States
- Registry updated
- 2024-11-19
CompletedNCT05557643
PAPR: Psilocybin-assisted Psychotherapy + Mindfulness-Based Stress Reduction (MBSR) for Front-line Healthcare Provider COVID-19 Related Burnout
University of Utah
- Conditions
- Depression · Burnout, Professional
- Phase
- Phase 1
- Enrollment
- 24 actual
- Locations
- Huntsman Mental Health Institute, Salt Lake City, Utah, United States
- Registry updated
- 2024-11-12
Active, not recruitingNCT05065294
An Open-Label Pilot Study Examining the Feasibility, Safety, and Effectiveness of Psilocybin Therapy for Depression in Bipolar II Disorder
University of California, San Francisco
- Conditions
- Bipolar II Disorder
- Phase
- Phase 2
- Enrollment
- 14 estimated
- Locations
- University of California, San Francisco, San Francisco, California, United States
- Registry updated
- 2024-09-25
CompletedNCT03300947
Psilocybin for Treatment of Obsessive Compulsive Disorder
University of Arizona
- Conditions
- Obsessive-compulsive Disorder (OCD)
- Phase
- Phase 1
- Enrollment
- 15 actual
- Locations
- University of Arizona, Tucson, Arizona, United States
- Registry updated
- 2024-08-30
Active, not recruitingNCT04433858
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
Sheppard Pratt Health System
- Conditions
- Treatment Resistant Depression
- Phase
- Phase 2
- Enrollment
- 27 actual
- Locations
- VA Palo Alto Healthcare System/Stanford Medicine, Palo Alto, California, United States · Sheppard Pratt Health System, Baltimore, Maryland, United States
- Registry updated
- 2024-08-09
CompletedNCT02243813
Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion
Johns Hopkins University
- Conditions
- Healthy
- Phase
- Phase 1
- Enrollment
- 24 actual
- Locations
- Behavioral Biology Research Center, Johns Hopkins Bayview, Baltimore, Maryland, United States
- Registry updated
- 2024-06-18
CompletedNCT04522804
A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer
University of Utah
- Conditions
- Cancer
- Phase
- Early Phase 1
- Enrollment
- 12 actual
- Locations
- Huntsman Cancer Institute, Salt Lake City, Utah, United States
- Registry updated
- 2024-03-20
CompletedNCT04218539
Repeat Dosing of Psilocybin in Headache Disorders
Yale University
- Conditions
- Migraine Headache
- Phase
- Phase 1
- Enrollment
- 18 actual
- Locations
- VA Connecticut Healthcare System, West Haven, Connecticut, United States
- Registry updated
- 2024-02-09
WithdrawnNCT05381974
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD
Massachusetts General Hospital
- Conditions
- Treatment-Resistant Major Depressive Disorder
- Phase
- Phase 2
- Enrollment
- 0 actual
- Locations
- Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts, United States
- Registry updated
- 2024-01-24
WithdrawnNCT00979693
Psilocybin-assisted Psychotherapy in the Management of Anxiety Associated With Stage IV Melanoma.
Multidisciplinary Association for Psychedelic Studies
- Conditions
- Anxiety · Stage IV Melanoma
- Phase
- Phase 2
- Enrollment
- 0 actual
- Locations
- Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
- Registry updated
- 2023-12-26
CompletedNCT02981173
Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders
Yale University
- Conditions
- Cluster Headache
- Phase
- Phase 1
- Enrollment
- 25 actual
- Locations
- VA Connecticut Healthcare System, West Haven, Connecticut, United States
- Registry updated
- 2023-12-15
CompletedNCT04739865
The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression
COMPASS Pathways
- Conditions
- Treatment Resistant Depression
- Phase
- Phase 2
- Enrollment
- 19 actual
- Locations
- Kadima Neuropsychiatry Institute, La Jolla, California, United States · Sheaf House, Tallaght Hospital, Dublin, Ireland
- Registry updated
- 2023-11-09
TerminatedNCT03806985
Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study II
Yale University
- Conditions
- Post-Traumatic Headache
- Phase
- Phase 1
- Enrollment
- 12 actual
- Locations
- VA Connecticut Healthcare System, West Haven, Connecticut, United States
- Registry updated
- 2023-10-12
CompletedNCT03341689
Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study I
Yale University
- Conditions
- Migraine Headache
- Phase
- Phase 1
- Enrollment
- 14 actual
- Locations
- VA Connecticut Healthcare System, West Haven Campus, West Haven, Connecticut, United States
- Registry updated
- 2023-10-12
CompletedNCT01534494
Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence
University of New Mexico
- Conditions
- Alcohol Dependence
- Phase
- Phase 2
- Enrollment
- 10 actual
- Locations
- University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States
- Registry updated
- 2023-09-26
CompletedNCT05478278
A Phase 1, Two-Part Study in Healthy Volunteers to Evaluate The Effect of Psilocybin on Cardiac Repolarization and The Effect of Food on Psilocybin Pharmacokinetics
Usona Institute
- Conditions
- QTc Interval · Pharmacokinetics
- Phase
- Phase 1
- Enrollment
- 60 actual
- Locations
- Altasciences Clinical Kansas, Inc, Overland Park, Kansas, United States
- Registry updated
- 2023-08-15
CompletedNCT04842045
Recall of Experience and Conscious Awareness in Psilocybin Treatment of Depression (The RECAP Study): Pilot Phase in Healthy Adult Volunteers
University of Wisconsin, Madison
- Conditions
- Psychedelic Experiences · Amnesia
- Phase
- Phase 1
- Enrollment
- 8 actual
- Locations
- UWHealth, 600 Highland Avenue, Madison, Wisconsin, United States
- Registry updated
- 2023-05-19
WithdrawnNCT05467761
A Phase 1 Study Comparing the Pharmacokinetics and Safety of Intravenous and Oral Psilocybin
University of Wisconsin, Madison
- Conditions
- Healthy
- Phase
- Phase 1
- Enrollment
- 0 actual
- Locations
- University of Wisconsin, Madison, Wisconsin, United States
- Registry updated
- 2023-05-15
CompletedNCT04052568
Effects of Psilocybin in Anorexia Nervosa
Johns Hopkins University
- Conditions
- Anorexia Nervosa
- Phase
- Phase 1
- Enrollment
- 22 actual
- Locations
- Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States
- Registry updated
- 2023-05-06
CompletedNCT03775200
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
COMPASS Pathways
- Conditions
- Treatment Resistant Depression
- Phase
- Phase 2
- Enrollment
- 233 actual
- Locations
- Kadima Neuropsychiatry Institute, La Jolla, California, United States · Altman Clinical and Translational Research Institute, University of California, San Diego, California, United States · Stanford Department of Psychiatry, Stanford, California, United States · +22 more
- Registry updated
- 2023-04-24
CompletedNCT04656301
Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder
New York State Psychiatric Institute
- Conditions
- Body Dysmorphic Disorders
- Phase
- Phase 2
- Enrollment
- 12 actual
- Locations
- New York State Psychiatric Institute, 1051 Riverside Drive, New York, New York, United States
- Registry updated
- 2023-03-13
WithdrawnNCT05601648
SV2A Marker of Synaptogenesis in a Clinical Trial of Psilocybin for Depression
Washington University School of Medicine
- Conditions
- Major Depressive Disorder · Anhedonia
- Phase
- Phase 2
- Enrollment
- 0 actual
- Locations
- Washington University School of Medicine, St Louis, Missouri, United States
- Registry updated
- 2023-01-30
Active, not recruitingNCT04410913
Pilot Trial of Visual Healing®, a Nature-themed Virtual Immersive Experience, to Optimize Set and Setting in Psilocybin-assisted Therapy for Alcohol Use Disorder
Keith Heinzerling
- Conditions
- Alcohol Use Disorder
- Phase
- Phase 2
- Enrollment
- 20 actual
- Locations
- Pacific Treatment & Research in Psychedelics, Santa Monica, California, United States
- Registry updated
- 2023-01-17
Unknown statusNCT05042466
NW Trauma Therapies, Chronic Illness of Chronic Depression, PTSD, MS, HIV, and SARS-CoV-2, Long Haulers Syndrome. Treatment of Unregulaaible Trauma by the Treatment of Enhanced Micro Dosing the Levels of 0.15, Thru 0.33, With a Maintenance Dose of 1 Gram Per Month for Neural Pathway Increase of Non Synthesized Psilocybin, Using the Actual Plant to Regulate the Highjacked Nervous System.
NWTraumatherapies
- Conditions
- Trauma, Nervous System
- Phase
- Phase 1
- Enrollment
- 30 estimated
- Locations
- Ross Allison NPI #1437519899 Administrator Of Study, Bozeman, Montana, United States
- Registry updated
- 2022-11-16
CompletedNCT02061293
A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence
NYU Langone Health
- Conditions
- Alcohol Dependence
- Phase
- Phase 2
- Enrollment
- 95 actual
- Locations
- University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States · Clinical and Translational Science Institute, NYU Langone Medical Center, New York, New York, United States
- Registry updated
- 2022-11-08
Unknown statusNCT04433845
The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.
Sheppard Pratt Health System
- Conditions
- Treatment Resistant Depression
- Phase
- Phase 2
- Enrollment
- 15 actual
- Locations
- Sheppard Pratt, Baltimore, Maryland, United States
- Registry updated
- 2022-10-25
CompletedNCT04519957
Multicentre Study To Assess Safety And Efficacy Of Psilocybin In Patients With Treatment-Resistant Depression Following Completion Of COMP 001 And COMP 003 Trials (P-TRD LTFU)
COMPASS Pathways
- Conditions
- Treatment Resistant Depression
- Phase
- Phase not reported
- Enrollment
- 66 actual
- Locations
- Kadima Neuropsychiatry Institute, La Jolla, California, United States · Altman Clinical and Translational Research Institute, University of California, San Diego, California, United States · Mood and Anxiety Disorders Program Emory University School of Medicine, Atlanta, Georgia, United States · +5 more
- Registry updated
- 2022-09-22
CompletedNCT04661514
Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy
University of California, San Diego
- Conditions
- Anorexia Nervosa
- Phase
- Phase 2
- Enrollment
- 16 actual
- Locations
- Altman Clinical and Translational Research Institute, La Jolla, California, United States
- Registry updated
- 2022-07-25
CompletedNCT02421263
A Randomized Controlled Trial of the Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion
NYU Langone Health
- Conditions
- Religious or Spiritual Problem
- Phase
- Phase 1
- Enrollment
- 12 actual
- Locations
- NYU Langone Medical Center/Tisch Hospital, New York, New York, United States
- Registry updated
- 2022-02-14
CompletedNCT03181529
Effects of Psilocybin in Major Depressive Disorder
Johns Hopkins University
- Conditions
- Major Depressive Disorder
- Phase
- Phase 2
- Enrollment
- 27 actual
- Locations
- Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
- Registry updated
- 2021-12-15
Unknown statusNCT04593563
The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder
Maryland Oncology Hematology, PA
- Conditions
- Major Depressive Disorder
- Phase
- Phase 2
- Enrollment
- 30 actual
- Locations
- Maryland Oncology Hematology PA, Rockville, Maryland, United States
- Registry updated
- 2021-10-15
CompletedNCT02950467
Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors
Joshua Woolley
- Conditions
- Distress · Depression · Grief
- Phase
- Phase 1
- Enrollment
- 30 actual
- Locations
- University of California, San Francisco, San Francisco, California, United States
- Registry updated
- 2021-01-07
CompletedNCT00957359
Effects of Psilocybin on Anxiety and Psychosocial Distress in Cancer Patients
NYU Langone Health
- Conditions
- Cancer
- Phase
- Early Phase 1
- Enrollment
- 29 actual
- Locations
- NYU College of Dentistry Bluestone Center for Clinical Research, New York, New York, United States
- Registry updated
- 2020-10-20
CompletedNCT02163707
Pharmacokinetics of Psilocybin in Normal Adult Volunteers
University of Wisconsin, Madison
- Conditions
- Healthy
- Phase
- Phase 1
- Enrollment
- 12 actual
- Locations
- University of Wisconsin, School of Pharmacy, Madison, Wisconsin, United States
- Registry updated
- 2020-04-15
CompletedNCT02145091
Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators
Johns Hopkins University
- Conditions
- Healthy
- Phase
- Phase 1
- Enrollment
- 40 actual
- Locations
- Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
- Registry updated
- 2019-12-30
CompletedNCT02971605
Measurement of Persisting Changes in Emotional Brain Functioning Produced by Psilocybin
Johns Hopkins University
- Conditions
- Healthy
- Phase
- Phase 1 · Phase 2
- Enrollment
- 13 actual
- Locations
- Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
- Registry updated
- 2019-09-10
CompletedNCT00465595
Psychopharmacology of Psilocybin in Cancer Patients
Johns Hopkins University
- Conditions
- Depressive Symptoms · Anxiety · Cancer
- Phase
- Phase 2
- Enrollment
- 56 actual
- Locations
- Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Campus, Baltimore, Maryland, United States
- Registry updated
- 2018-07-19
CompletedNCT00802282
Effects of Psilocybin and Spiritual Practice on Persisting Changes in Attitudes and Behavior
Johns Hopkins University
- Conditions
- Healthy
- Phase
- Phase 1
- Enrollment
- 75 actual
- Locations
- Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
- Registry updated
- 2016-02-24
CompletedNCT01988311
Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators
Johns Hopkins University
- Conditions
- Psilocybin · Hallucinogens · Pharmacologic Actions · Central Nervous System Agents
- Phase
- Phase 1
- Enrollment
- 10 estimated
- Locations
- Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
- Registry updated
- 2014-05-20
Related research views
Continue exploring clinical trials
Move between curated condition, country, phase, and recruiting views without losing direct source provenance.
Recruitment
Conditions
Countries
- United States trials
- Canada trials
- United Kingdom trials
- Switzerland trials
Phases
Method and accountability
How this collection is maintained
Automatic refresh: counts, facets, records, and the map update from the tracker after scheduled ClinicalTrials.gov refreshes. The registry remains authoritative.
Rights-safe scope: the page exposes allowlisted factual metadata. Registry descriptions, contacts, raw payloads, and source-derived keywords are not redistributed.
Editorial review: collection definitions, limitations, corrections, and authorship are documented in the editorial and methodology policy.